PMID- 35302581
OWN - NLM
STAT- MEDLINE
DCOM- 20221201
LR  - 20230109
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Print)
IS  - 1462-0324 (Linking)
VI  - 61
IP  - 12
DP  - 2022 Nov 28
TI  - Impact of remission and low disease activity on health-related quality of life in 
      patients with systemic lupus erythematosus.
PG  - 4752-4762
LID - 10.1093/rheumatology/keac185 [doi]
AB  - OBJECTIVES: To investigate the impact of remission and lupus low disease activity 
      state (LLDAS) on health-related quality of life (HRQoL) in systemic lupus 
      erythematosus. METHODS: Short-Form 36 (SF-36), three-level EQ-5D (EQ-5D-3L) and 
      Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue data from the 
      BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials were used. Duration in 
      remission/LLDAS required to reach a HRQoL benefit >/= minimal clinically important 
      differences (MCIDs) during and post-treatment was determined using quantile 
      regression and generalized estimating equations. RESULTS: Patients (n = 1684) 
      were assessed every fourth week (15 visits). Four cumulative (beta = 0.60) or four 
      consecutive (beta = 0.66) visits in remission were required to achieve a benefit 
      >/=MCID in SF-36 physical component summary (PCS) scores, and six cumulative 
      (beta = 0.44) or five consecutive (beta = 0.49) for a benefit >/=MCID in mental component 
      summary (MCS) scores. Eight cumulative (beta = 0.30 for both) or eight consecutive 
      (beta = 0.32 for both) visits in LLDAS were required for a benefit in PCS/MCS >/=MCID, 
      respectively. For EQ-5D-3L index scores >/=MCID, six cumulative (beta = 0.007) or five 
      consecutive (beta = 0.008) visits in remission were required, and eight cumulative 
      (beta = 0.005) or six consecutive (beta = 0.006) visits in LLDAS. For FACIT-Fatigue 
      scores >/=MCID, 12 cumulative (beta = 0.34) or 10 consecutive (beta = 0.39) visits in 
      remission were required, and 17 cumulative (beta = 0.24) or 16 consecutive 
      (beta = 0.25) visits in LLDAS. CONCLUSION: Remission and LLDAS contribute to a HRQoL 
      benefit in a time-dependent manner. Shorter time in remission than in LLDAS was 
      required for a clinically important benefit in HRQoL, and longer time in 
      remission for a benefit in mental compared with physical HRQoL aspects. When 
      remission/LLDAS was sustained, the same benefit was achieved in a shorter time.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the 
      British Society for Rheumatology.
FAU - Emamikia, Sharzad
AU  - Emamikia S
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Oon, Shereen
AU  - Oon S
AD  - Departments of Medicine and Rheumatology, The University of Melbourne at St 
      Vincent's Hospital, Fitzroy.
FAU - Gomez, Alvaro
AU  - Gomez A
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Lindblom, Julius
AU  - Lindblom J
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Borg, Alexander
AU  - Borg A
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Enman, Yvonne
AU  - Enman Y
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Morand, Eric
AU  - Morand E
AUID- ORCID: 0000-0002-9507-3338
AD  - School of Clinical Sciences at Monash Health, Monash University Faculty of 
      Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Clayton, 
      Victoria, Australia.
FAU - Grannas, David
AU  - Grannas D
AD  - Divison of Biostatistics, Institute of Environmental Medicine, Karolinska 
      Institutet, Stockholm, Sweden.
FAU - van Vollenhoven, Ronald F
AU  - van Vollenhoven RF
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden.
AD  - Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, 
      Amsterdam, The Netherlands.
FAU - Nikpour, Mandana
AU  - Nikpour M
AD  - Departments of Medicine and Rheumatology, The University of Melbourne at St 
      Vincent's Hospital, Fitzroy.
FAU - Parodis, Ioannis
AU  - Parodis I
AUID- ORCID: 0000-0002-4875-5395
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden.
AD  - Department of Rheumatology, Faculty of Medicine and Health, Orebro University, 
      Orebro, Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT00424476
SI  - ClinicalTrials.gov/NCT00410384
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
SB  - IM
MH  - Humans
MH  - *Quality of Life
MH  - *Lupus Erythematosus, Systemic/drug therapy
MH  - Minimal Clinically Important Difference
MH  - Fatigue/etiology
MH  - Causality
MH  - Severity of Illness Index
PMC - PMC9707321
OTO - NOTNLM
OT  - SLE
OT  - health-related quality of life
OT  - lupus low disease activity state
OT  - remission
OT  - treat-to-target
EDAT- 2022/03/19 06:00
MHDA- 2022/12/02 06:00
PMCR- 2022/03/18
CRDT- 2022/03/18 12:11
PHST- 2021/11/30 00:00 [received]
PHST- 2022/03/12 00:00 [revised]
PHST- 2022/03/19 06:00 [pubmed]
PHST- 2022/12/02 06:00 [medline]
PHST- 2022/03/18 12:11 [entrez]
PHST- 2022/03/18 00:00 [pmc-release]
AID - 6550500 [pii]
AID - keac185 [pii]
AID - 10.1093/rheumatology/keac185 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2022 Nov 28;61(12):4752-4762. doi: 
      10.1093/rheumatology/keac185.